Roche
Note: This is a daily stock update and the information stands true as of 09/03/26, 09:00 CET.
Company Update:
Roche’s investigational breast cancer drug, Giredestrant, did not meet the objectives in a phase III trial, wherein Giredestrant was tested in combination with Pfizer’s Ibrance as a first-line treatment for ER+/HER2- metastatic breast cancer (endocrine-sensitive). Nonetheless, this was only one of the two separate phase III studies in the first-line setting, and the results of the other phase III study evaluating Giredestrant in combination with physician’s choice of CDK4/6 inhibitor in endocrine-resistant ER-positive breast cancer are expected in 2027. Endocrine resistance in breast cancer occurs when estrogen receptor-positive (ER+) cancer cells stop responding to hormone therapies.
Giredestrant could still become a blockbuster drug for Roche, however, for today, we expect a negative share price reaction.
Expert Opinion:
Momentum is getting more negative for Roche and its valuation is no longer substantially below peers (PE16 and 17 at 16.1x and 15.4x). While the underlying quality of the company cannot be disputed, we expect short term pressure on the name. There are probably better opportunities in the sector (dare we mention Novo?).
For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Company Update:
Roche’s investigational breast cancer drug, Giredestrant, did not meet the objectives in a phase III trial, wherein Giredestrant was tested in combination with Pfizer’s Ibrance as a first-line treatment for ER+/HER2- metastatic breast cancer (endocrine-sensitive). Nonetheless, this was only one of the two separate phase III studies in the first-line setting, and the results of the other phase III study evaluating Giredestrant in combination with physician’s choice of CDK4/6 inhibitor in endocrine-resistant ER-positive breast cancer are expected in 2027. Endocrine resistance in breast cancer occurs when estrogen receptor-positive (ER+) cancer cells stop responding to hormone therapies.
Giredestrant could still become a blockbuster drug for Roche, however, for today, we expect a negative share price reaction.
Expert Opinion:
Momentum is getting more negative for Roche and its valuation is no longer substantially below peers (PE16 and 17 at 16.1x and 15.4x). While the underlying quality of the company cannot be disputed, we expect short term pressure on the name. There are probably better opportunities in the sector (dare we mention Novo?).
For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Subscribe to our blog
